Risks and benefits of phase 1 clinical trials evaluating new anticancer agents - A case for more innovation

被引：17

作者：

Chen, EX

Tannock, IF

机构：

[1] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2004年 / 292卷 / 17期

关键词：

D O I：

10.1001/jama.292.17.2150

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2150 / 2151

页数：2

共 11 条

[1] Ethics of phase 1 oncology studies - Reexamining the arguments and data [J].

Agrawal, M ;

Emanuel, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (08) :1075-1082

[2] RESPONSES AND TOXIC DEATHS IN PHASE-I CLINICAL-TRIALS [J].

DECOSTER, G ;

STEIN, G ;

HOLDENER, EE .

ANNALS OF ONCOLOGY, 1990, 1 (03) :175-181

[3]

Dent SF, 1996, ANN ONCOL, V7, P561

[4] Phase I clinical trial design in cancer drug development [J].

Eisenhauer, EA ;

O'Dwyer, PJ ;

Christian, M ;

Humphrey, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :684-692

[5] THERAPEUTIC RESPONSE AND POTENTIAL PITFALLS IN PHASE-I CLINICAL-TRIALS OF ANTICANCER AGENTS CONDUCTED IN JAPAN [J].

ITOH, K ;

SASAKI, Y ;

MIYATA, Y ;

FUJII, H ;

OHTSU, T ;

WAKITA, H ;

IGARASHI, T ;

ABE, K .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 (06) :451-454

[6] Factors associated with failure to publish large randomized trials presented at an oncology meeting [J].

Krzyzanowska, MK ;

Pintilie, M ;

Tannock, IF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :495-501

[7] Perceptions of patients and physicians regarding phase I cancer clinical trials: Implications for physician-patient communication [J].

Meropol, NJ ;

Weinfurt, KP ;

Burnett, CB ;

Balshem, A ;

Benson, AB ;

Castel, L ;

Corbett, S ;

Diefenbach, M ;

Gaskin, D ;

Li, Y ;

Manne, S ;

Marshall, J ;

Rowland, JH ;

Slater, E ;

Sulmasy, DP ;

Van Echo, D ;

Washington, S ;

Schulman, KA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2589-2596

[8] Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice [J].

Parulekar, WR ;

Eisenhauer, EA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (13) :990-997

[9] Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials [J].

Roberts, TG ;

Goulart, BH ;

Squitieri, L ;

Stallings, SC ;

Halpern, EF ;

Chabner, BA ;

Gazelle, GS ;

Finkelstein, SN ;

Clark, JW .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (17) :2130-2140

[10] Accelerated titration designs for phase I clinical trials in oncology [J].

Simon, R ;

Freidlin, B ;

Rubinstein, L ;

Arbuck, SG ;

Collins, J ;

Christian, MC .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (15) :1138-1147

← 1 2 →